May be useful when evaluating for systemic sclerosis or connective tissue disease associated with overlapping features of systemic sclerosis and/or myositis.
Tue, Thu, Sat
Serum separator tube.
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Plasma. Contaminated, hemolyzed, or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), and polymyositis/systemic sclerosis overlap syndrome. The clinical relevance of PM/Scl-100 IgG antibody with a negative ANA IFA nucleolar pattern is unknown. PM/Scl-100 is the main target epitope of the PM/Scl complex, although antibodies to other targets not detected by this assay may occur.
Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|2003041||PM/Scl 100 Antibody, IgG||81732-0|
- Antinuclear Antibodies
- Antinuclear Antibody
- Fluorescent Antinuclear Antibodies
- PM/Sci-100 IgG
- PM1 Antibody